Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study

Liu, Yanmei; Ni, Lingqin; Wang, Saisai; Qian-ling, LV; Chen, Weijun; Ying, Shenpeng

doi:10.1186/s12957-017-1307-0

Cited by 39 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports showed most of patients with cervical cancer in early stages (I-II), who accepted proper treatment always gained the great benefits, with only 10% to 15% of the patients suffering recurrence or other bad outcomes 25 . Therefore, the timely and accurate diagnosis to identify the status of cancer development were particularly necessary before treatment.…”

Section: Discussionmentioning

confidence: 99%

Area-specific economic status should be regarded as a vital factor affecting the occurrence, development and outcome of cervical cancer

et al. 2020

Sci Rep

View full text Add to dashboard Cite

For patients with cervical cancer, despite the incidence and mortality rates have been declining in recent years, due to its huge population base, cervical cancer has always been a serious public health problem. Our research placed emphasis on the indices greatly associated with overall area-specific social economic status, making up for the defects of traditional research which only pay attention to the situation of some specific disease or patients' individual social status. A total of 39160 women identified cervical cancer were concluded in our study from the Surveillance, Epidemiology, and End Results (SEER) 18 Program data between 1980 and 2014. With improving the area-specific social economic factors in recent years, the occurrence and prognosis of cervical cancer showed different variation patterns respectively. Some states like California and Georgia for their better economic status and more healthcare investment by local medical institution, population there showed a lower prevalence, incidence, more timely diagnosis, effective treatment, and better prognosis. According to our study, we aimed to give a scientific interpretation on how the area-specific social economic factors affect the disease situation at the macro level and help local medical institution make advisable decisions for controlling cervical cancer.Cervical cancer is the fourth most frequent diagnosed cancer type 1 and the third leading cause of cancer deaths among females in the world. In United States, it was also regarded as an important public health problem, for nearly 250,000 women currently live with the cervical cancer 2 , 12,820 new cases' occurrence and 4,210 patients' deaths annually 3 .With the progress in research targeting to cervical cancer, infection of the Human Papilloma virus (HPV) was confirmed as a vital etiologic risk factor of cervical cancer. Due to the promotion of first screening, the incidence and the mortality rates decreased gradually though early intervention and reduction of the risk factors 4 . As a result, cervical cancer became a preventable disease in general population.In recent years, more and more women got benefits from medical development under the support by local economic institution, for spreading HPV vaccine since 2006 4 and applying many advanced treatment gradually. However, in some underdeveloped areas, most women still suffered undiagnosed and had limited access to proper treatment or prevention in their daily life 5-8 . These differences might derive from many aspects. According to previous studies, variation of patients' incidence rates and outcome have been greatly associated with ages, tumor histology, tumor differentiation 7,9,10 , and individual socioeconomic status, including race/ethnicity and insurance status [11][12][13] . However, the overall social economic factors have been ignored, which may be greatly associated

show abstract

Section: Discussionmentioning

confidence: 99%

Area-specific economic status should be regarded as a vital factor affecting the occurrence, development and outcome of cervical cancer

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A total of 50 patients were enrolled, (range, 45-71 years) and the mean age was 60.1±3.5 years old. A total of 50 cases were divided into four groups, according to their clinical features and the TNM stage system (14): Stage I, 7 cases; stage II, 19 cases; stage III, 9 cases and stage IV, 15 cases. Non-cancerous tissues were taken >5 cm from the tumor site and confirmed by a pathologist as normal tissue.…”

Section: Methodsmentioning

confidence: 99%

Long non‑coding RNA RP11‑480I12.5 promotes cervical carcinoma progression by regulating the Wnt/β‑catenin signaling pathway

Zhang¹,

Sona³

2019

Oncol Lett

View full text Add to dashboard Cite

T he long non-coding R NA (lncR NA), RP11-480I12.5 is one of the most dysregulated lncRNAs, which is believed to contribute to the progression of cervical carcinoma (CC); however, the exact function of RP11-480I12.5 in human CC remains unknown. The present study aimed to investigate the function and underlying molecular mechanism of RP11-480I12.5 in CC. First, reverse transcription-quantitative PCR was implemented in order to detect differences in the expression of RP11-480I12.5 between normal and CC tissues. The present study used in vitro analysis to establish RP11-480I12.5 stable knockdown and overexpressing cell lines, in order to investigate the function and potential molecular mechanism of RP11-480I12.5 in the progression of CC. RP11-480I12.5 was upregulated in CC tissue compared with normal tissue. Furthermore, RP11-480I12.5 was associated with clinical stage, tumor size and lymph node metastasis. RP11-480I12.5 promoted the proliferation, migration and invasion of CC cell lines. Subsequently, the present study investigated the association between RP11-480I12.5 and the epithelial-to-mesenchymal transition (EMT) and Wnt/β-catenin pathways. RP11-480I12.5 promoted EMT through the Wnt/β-catenin pathway. Overall, the results of the present study demonstrate that RP11-480I12.5 promotes cercical cancer cell migration, invasion and EMT through the Wnt/β-catenin pathway.

show abstract

“…A set of six MRI planning data sets from patients who had been previously treated with EBRT followed by cervix HDR brachytherapy were used as a representative sample in this study. A planning MRI scan was obtained with a resolution of 0.5 × 0.5 × 4 mm 3 fractions. Target volume delineation, treatment planning, and dose concepts were made in accordance with the GEC-ESTRO recommendations and the EMBRACE protocol guidelines [18,38,39].…”

Section: A Treatment Planningmentioning

confidence: 99%

“…It ranked second for both incidence and mortality in the lower Human Development Index (HDI) among women [1,2]. According to previous reports, cervical cancer patients with initial stages (stages IB -IIA) who undergo appropriate treatment will develop recurrence with a risk factor of 10 -15% [3,4]. Therefore, early diagnosis and treatment of cervical cancer are crucial for reducing the mortality rate.…”

Section: Introductionmentioning

confidence: 99%

Robust Optimization to Reduce Dose Delivery Uncertainty by Potential Applicator Displacements for a Cervix Brachytherapy

Park²,

Kim³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Applicator displacement during brachytherapy treatment for cervical cancer leads to a drastic change in dose distribution. Hence, applicator displacement uncertainty is of significant relevance within the distribution of dose prescription. To minimize applicator displacement from patient movement during cervical cancer brachytherapy treatment, a multi-objective genetic algorithm was combined with a median absolute deviation (MAD) constrained robust optimization concept. Materials and methods To evaluate the feasibility of the robust optimization algorithm on applicator displacements, the clinically applied treatment plans of six tandem and ring (T&R) applicator cases for cervical cancer were included. All patients underwent magnetic resonance imaging (MRI) after the placement of the T&R applicator. The method considered multiple random scenarios reflecting the uncertainties in the dose delivered. For simplicity, the uncertainties in this proof-of-concept study were limited to potential applicator displacements. This problem is optimized by MAD-constrained robust optimization using a patient-specific multi-objective genetic algorithm. The proposed approach is then compared against the nominal (manual) plan strategies. Results All generated plans fulfilled EMBRACE protocol guidelines for all targets and organs at risk (OAR). MAD-constrained robust optimization provided not only excellent target coverage but also minimized doses to OAR. The nominal and robust plan equivalent dose in 2 Gy fractions (EQD2) of D98 for high-risk clinical target volume (HR-CTV) and rectum were 88.59, 55.29, and 84.84, 54.09, respectively. Furthermore, each standard deviation of D98 for HR-CTV and rectum reduced from ±1.0177 to ±0.9085 and ±0.4927 to ±0.4052, respectively. Conclusions Definitive dwell times and positions by the use of robust planned external beam radiation therapy plus brachytherapy (EBRT-BT) boost for cervical cancer were well tolerated. Using this robust strategy, the generated plans showed an increase in target coverage and minimized applicator displacement impact uncertainty on dose delivery.

show abstract

Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study

Cited by 39 publications

References 28 publications

Area-specific economic status should be regarded as a vital factor affecting the occurrence, development and outcome of cervical cancer

Area-specific economic status should be regarded as a vital factor affecting the occurrence, development and outcome of cervical cancer

Long non‑coding RNA RP11‑480I12.5 promotes cervical carcinoma progression by regulating the Wnt/β‑catenin signaling pathway

Robust Optimization to Reduce Dose Delivery Uncertainty by Potential Applicator Displacements for a Cervix Brachytherapy

Contact Info

Product

Resources

About